Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist. To address this critical ...

Biological scientists have uncovered how the dengue virus uses its envelope protein to capture human plasmin from a blood meal to enhance the permeability of the mosquito midgut for infection.

Press Release   FROM THE MINISTRY OF HEALTH AND HUMAN SERVICES Providenciales, Turks and Caicos Islands, 3rd February 2025 ...

Biological scientists from the National University of Singapore (NUS) have uncovered how the dengue virus uses its envelope ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...